['HIV-ANTIVIRAL AGENTS', 'NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR: DELAVIRDINE INVIRASE/RITONAVIR INTERACTION HAS NOT BEEN EVALUATED.', '\xe2\x86\x91 SAQUINAVIR EFFECT ON DELAVIRDINE IS NOT WELL ESTABLISHED', 'APPROPRIATE DOSES OF THE COMBINATION WITH RESPECT TO SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.', 'NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR: EFAVIRENZ SEE CLINICAL PHARMACOLOGY: PHARMACOKINETICS , TABLE 2 AND TABLE 3 FOR MAGNITUDE OF INTERACTIONS. , NEVIRAPINE', '\xe2\x86\x93 SAQUINAVIR \xe2\x86\x94 EFAVIRENZ', 'APPROPRIATE DOSES OF THE COMBINATION OF EFAVIRENZ OR NEVIRAPINE AND INVIRASE/RITONAVIR (1000/100 MG BID) WITH RESPECT TO SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.', 'HIV PROTEASE INHIBITOR: ATAZANAVIR', 'INVIRASE/RITONAVIR \xe2\x86\x91 SAQUINAVIR \xe2\x86\x91 RITONAVIR \xe2\x86\x94 ATAZANAVIR', 'APPROPRIATE DOSING RECOMMENDATIONS FOR THIS COMBINATION, WITH RESPECT TO EFFICACY AND SAFETY, HAVE NOT BEEN ESTABLISHED. WHEN 1600 MG INVIRASE/100 MG RITONAVIR AND 300 MG ATAZANAVIR WERE COADMINISTERED, PLASMA CONCENTRATIONS OF SAQUINAVIR AND RITONAVIR WERE INCREASED.', 'HIV PROTEASE INHIBITOR: INDINAVIR', '\xe2\x86\x91 SAQUINAVIR EFFECT ON INDINAVIR IS NOT WELL ESTABLISHED', 'APPROPRIATE DOSES OF THE COMBINATION OF INDINAVIR AND INVIRASE/RITONAVIR WITH RESPECT TO SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.', 'HIV PROTEASE INHIBITOR: LOPINAVIR/RITONAVIR (COFORMULATED CAPSULE)', '\xe2\x86\x94 SAQUINAVIR \xe2\x86\x94 LOPINAVIR \xe2\x86\x93 RITONAVIR', 'EVIDENCE FROM SEVERAL CLINICAL TRIALS INDICATES THAT SAQUINAVIR CONCENTRATIONS ACHIEVED WITH THE SAQUINAVIR AND LOPINAVIR/RITONAVIR COMBINATION ARE SIMILAR TO THOSE ACHIEVED FOLLOWING SAQUINAVIR/RITONAVIR 1000/100 MG. THE RECOMMENDED DOSE FOR THIS COMBINATION IS SAQUINAVIR 1000 MG PLUS LOPINAVIR/RITONAVIR 400/100 MG BID.', 'HIV PROTEASE INHIBITOR: TIPRANAVIR/RITONAVIR', '\xe2\x86\x93 SAQUINAVIR', 'COMBINING SAQUINAVIR WITH TIPRANAVIR/RITONAVIR IS NOT RECOMMENDED.', 'HIV FUSION INHIBITOR: ENFUVIRTIDE', 'SAQUINAVIR SOFT GEL CAPSULES/RITONAVIR \xe2\x86\x94 ENFUVIRTIDE', 'NO CLINICALLY SIGNIFICANT INTERACTION WAS NOTED FROM A STUDY IN 12 HIV PATIENTS WHO RECEIVED ENFUVIRTIDE CONCOMITANTLY WITH SAQUINAVIR SOFT GEL CAPSULES/RITONAVIR 1000/100 MG BID. NO DOSE ADJUSTMENTS ARE REQUIRED.', 'OTHER AGENTS', 'ANTIARRHYTHMICS: LIDOCAINE (SYSTEMIC)', '\xe2\x86\x91 ANTIARRHYTHMICS', 'CAUTION IS WARRANTED AND THERAPEUTIC CONCENTRATION MONITORING, IF AVAILABLE, IS RECOMMENDED FOR ANTIARRHYTHMICS GIVEN WITH INVIRASE/RITONAVIR.', 'ANTICOAGULANT: WARFARIN', '\xe2\x86\x91 WARFARIN', 'CONCENTRATIONS OF WARFARIN MAY BE AFFECTED. IT IS RECOMMENDED THAT INR (INTERNATIONAL NORMALIZED RATIO) BE MONITORED.', 'ANTICONVULSANTS: CARBAMAZEPINE , PHENOBARBITAL , PHENYTOIN', '\xe2\x86\x93 SAQUINAVIR EFFECT ON CARBAMAZEPINE, PHENOBARBITAL, AND PHENYTOIN IS NOT WELL ESTABLISHED', 'USE WITH CAUTION, SAQUINAVIR MAY BE LESS EFFECTIVE DUE TO DECREASED SAQUINAVIR PLASMA CONCENTRATIONS IN PATIENTS TAKING THESE AGENTS CONCOMITANTLY.', 'ANTI-INFECTIVE: CLARITHROMYCIN', '\xe2\x86\x91 SAQUINAVIR \xe2\x86\x91 CLARITHROMYCIN', 'APPROPRIATE DOSES OF THE COMBINATION OF CLARITHROMYCIN AND INVIRASE/RITONAVIR WITH RESPECT TO SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED. DUE TO THE KNOWN EFFECT OF RITONAVIR ON CLARITHROMYCIN CONCENTRATIONS, THE FOLLOWING DOSE ADJUSTMENTS ARE RECOMMENDED: FOR PATIENTS WITH RENAL IMPAIRMENT, THE FOLLOWING DOSAGE ADJUSTMENTS SHOULD BE CONSIDERED: FOR PATIENTS WITH CL CR 30 TO 60 ML/MIN THE DOSE OF CLARITHROMYCIN SHOULD BE REDUCED BY 50%. FOR PATIENTS WITH CL CR <30 ML/MIN THE DOSE OF CLARITHROMYCIN SHOULD BE DECREASED BY 75%. NO DOSE ADJUSTMENT FOR PATIENTS WITH NORMAL RENAL FUNCTION IS NECESSARY.', 'ANTIFUNGAL: KETOCONAZOLE , ITRACONAZOLE', '\xe2\x86\x94 SAQUINAVIR \xe2\x86\x94 RITONAVIR \xe2\x86\x91 KETOCONAZOLE', 'APPROPRIATE DOSES OF THE COMBINATION OF KETOCONAZOLE OR ITRACONAZOLE AND INVIRASE/RITONAVIR WITH RESPECT TO SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED. WHEN INVIRASE/RITONAVIR AND KETOCONAZOLE ARE COADMINISTERED, PLASMA CONCENTRATION OF KETOCONAZOLE WAS INCREASED (SEE TABLE 2 ). HENCE, DOSES OF KETOCONAZOLE > 200 MG/DAY ARE NOT RECOMMENDED.', 'ANTIMYCOBACTERIAL: RIFABUTIN', '\xe2\x86\x93 SAQUINAVIR \xe2\x86\x91 RIFABUTIN', 'APPROPRIATE DOSES OF THE COMBINATION OF RIFABUTIN AND INVIRASE/RITONAVIR WITH RESPECT TO SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.', 'BENZODIAZEPINES : ALPRAZOLAM, CLORAZEPATE, DIAZEPAM, FLURAZEPAM', '\xe2\x86\x91 BENZODIAZEPINES', 'CLINICAL SIGNIFICANCE IS UNKNOWN; HOWEVER, A DECREASE IN BENZODIAZEPINE DOSE MAY BE NEEDED.', 'BENZODIAZEPINE : INTRAVENOUSLY ADMINISTERED MIDAZOLAM', '\xe2\x86\x91 MIDAZOLAM', 'MIDAZOLAM IS EXTENSIVELY METABOLIZED BY CYP3A4. INCREASES IN THE CONCENTRATION OF MIDAZOLAM ARE EXPECTED TO BE SIGNIFICANTLY HIGHER WITH ORAL THAN PARENTERAL ADMINISTRATION. THEREFORE, INVIRASE SHOULD NOT BE GIVEN WITH ORALLY ADMINISTERED MIDAZOLAM [SEE CONTRAINDICATIONS (4) ]. IF INVIRASE IS COADMINISTERED WITH PARENTERAL MIDAZOLAM, CLOSE CLINICAL MONITORING FOR RESPIRATORY DEPRESSION AND/OR PROLONGED SEDATION SHOULD BE EXERCISED AND DOSAGE ADJUSTMENT SHOULD BE CONSIDERED.', 'CALCIUM CHANNEL BLOCKERS : DILTIAZEM, FELODIPINE, NIFEDIPINE, NICARDIPINE, NIMODIPINE, VERAPAMIL, AMLODIPINE, NISOLDIPINE, ISRADIPINE', '\xe2\x86\x91 CALCIUM CHANNEL BLOCKERS', 'CAUTION IS WARRANTED AND CLINICAL MONITORING OF PATIENTS IS RECOMMENDED.', 'CORTICOSTEROID: DEXAMETHASONE', '\xe2\x86\x93 SAQUINAVIR', 'USE WITH CAUTION, SAQUINAVIR MAY BE LESS EFFECTIVE DUE TO DECREASED SAQUINAVIR PLASMA CONCENTRATIONS IN PATIENTS TAKING THESE AGENTS CONCOMITANTLY.', 'DIGITALIS GLYCOSIDES: DIGOXIN', '\xe2\x86\x91 DIGOXIN INCREASES IN SERUM DIGOXIN CONCENTRATION WERE GREATER IN FEMALE SUBJECTS AS COMPARED TO MALE SUBJECTS WHEN DIGOXIN WAS COADMINISTERED WITH INVIRASE/RITONAVIR.', 'CONCOMITANT USE OF INVIRASE/RITONAVIR WITH DIGOXIN RESULTS IN A SIGNIFICANT INCREASE IN SERUM CONCENTRATIONS OF DIGOXIN. CAUTION SHOULD BE EXERCISED WHEN INVIRASE/RITONAVIR AND DIGOXIN ARE COADMINISTERED; SERUM DIGOXIN CONCENTRATIONS SHOULD BE MONITORED AND THE DOSE OF DIGOXIN MAY NEED TO BE REDUCED WHEN COADMINISTERED WITH INVIRASE/RITONAVIR (SEE WARNINGS ).', 'INHALED/NASAL STEROID: FLUTICASONE', 'INVIRASE/RITONAVIR \xe2\x86\x91 FLUTICASONE', 'CONCOMITANT USE OF FLUTICASONE PROPIONATE AND INVIRASE/RITONAVIR MAY INCREASE PLASMA CONCENTRATIONS OF FLUTICASONE PROPIONATE, RESULTING IN SIGNIFICANTLY REDUCED SERUM CORTISOL CONCENTRATIONS. COADMINISTRATION OF FLUTICASONE PROPIONATE AND INVIRASE/RITONAVIR IS NOT RECOMMENDED UNLESS THE POTENTIAL BENEFIT TO THE PATIENT OUTWEIGHS THE RISK OF SYSTEMIC CORTICOSTEROID SIDE EFFECTS (SEE WARNINGS ).', 'HMG-COA REDUCTASE INHIBITORS : ATORVASTATIN, ROSUVASTATIN', '\xe2\x86\x91 ATORVASTATIN \xe2\x86\x91 ROSUVASTATIN', 'USE LOWEST POSSIBLE DOSE OF ATORVASTATIN OR ROSUVASTATIN WITH CAREFUL MONITORING, OR CONSIDER OTHER HMG-COA REDUCTASE INHIBITORS SUCH AS FLUVASTATIN IN COMBINATION WITH INVIRASE/RITONAVIR (SEE WARNINGS ).', 'IMMUNOSUPPRESSANTS : CYCLOSPORINE, TACROLIMUS, RAPAMYCIN', '\xe2\x86\x91 IMMUNOSUPPRESSANTS', 'THERAPEUTIC CONCENTRATION MONITORING IS RECOMMENDED FOR IMMUNOSUPPRESSANT AGENTS WHEN COADMINISTERED WITH INVIRASE/RITONAVIR.', 'NARCOTIC ANALGESIC: METHADONE', '\xe2\x86\x93 METHADONE', 'DOSAGE OF METHADONE MAY NEED TO BE INCREASED WHEN COADMINISTERED WITH INVIRASE/RITONAVIR.', 'ORAL CONTRACEPTIVES: ETHINYL ESTRADIOL', '\xe2\x86\x93 ETHINYL ESTRADIOL', 'ALTERNATIVE OR ADDITIONAL CONTRACEPTIVE MEASURES SHOULD BE USED WHEN ESTROGEN-BASED ORAL CONTRACEPTIVES AND INVIRASE/RITONAVIR ARE COADMINISTERED.', 'PDE5 INHIBITORS (PHOSPHODIESTERASE TYPE 5 INHIBITORS): SILDENAFIL , VARDENAFIL , TADALAFIL', '\xe2\x86\x91 SILDENAFIL \xe2\x86\x94 SAQUINAVIR \xe2\x86\x91 VARDENAFIL \xe2\x86\x91 TADALAFIL', 'USE SILDENAFIL WITH CAUTION AT REDUCED DOSES OF 25 MG EVERY 48 HOURS WITH INCREASED MONITORING OF ADVERSE EVENTS WHEN ADMINISTERED CONCOMITANTLY WITH INVIRASE/RITONAVIR. USE VARDENAFIL WITH CAUTION AT REDUCED DOSES OF NO MORE THAN 2.5 MG EVERY 72 HOURS WITH INCREASED MONITORING OF ADVERSE EVENTS WHEN ADMINISTERED CONCOMITANTLY WITH INVIRASE/RITONAVIR. USE TADALAFIL WITH CAUTION AT REDUCED DOSES OF NO MORE THAN 10 MG EVERY 72 HOURS WITH INCREASED MONITORING OF ADVERSE EVENTS WHEN ADMINISTERED CONCOMITANTLY WITH INVIRASE/RITONAVIR.', 'ANTIDEPRESSANT: TRAZODONE', '\xe2\x86\x91 TRAZODONE', 'CONCOMITANT USE OF TRAZODONE AND INVIRASE/RITONAVIR MAY INCREASE PLASMA CONCENTRATION OF TRAZODONE. ADVERSE EVENTS OF NAUSEA, DIZZINESS, HYPOTENSION AND SYNCOPE HAVE BEEN OBSERVED FOLLOWING COADMINISTRATION OF TRAZODONE AND RITONAVIR. IF TRAZODONE IS USED WITH A CYP3A4 INHIBITOR SUCH AS INVIRASE/RITONAVIR, THE COMBINATION SHOULD BE USED WITH CAUTION AND LOWER DOSE OF TRAZODONE SHOULD BE CONSIDERED.', 'TRICYCLIC ANTIDEPRESSANTS : AMITRIPTYLINE, IMIPRAMINE', '\xe2\x86\x91 TRICYCLICS', 'THERAPEUTIC CONCENTRATION MONITORING IS RECOMMENDED FOR TRICYCLIC ANTIDEPRESSANTS WHEN COADMINISTERED WITH INVIRASE/RITONAVIR.', 'PROTON PUMP INHIBITORS: OMEPRAZOLE', '\xe2\x86\x91 SAQUINAVIR', 'WHEN INVIRASE/RITONAVIR IS CO-ADMINISTERED WITH OMEPRAZOLE, SAQUINAVIR CONCENTRATIONS ARE INCREASED SIGNIFICANTLY. IF OMEPRAZOLE OR ANOTHER PROTON PUMP INHIBITOR IS TAKEN CONCOMITANTLY WITH INVIRASE/RITONAVIR, CAUTION IS ADVISED AND MONITORING FOR POTENTIAL SAQUINAVIR TOXICITIES IS RECOMMENDED, PARTICULARLY GASTROINTESTINAL SYMPTOMS, INCREASED TRIGLYCERIDES, AND DEEP VEIN THROMBOSIS.', "HERBAL PRODUCTS: ST. JOHN'S WORT (HYPERICUM PERFORATUM)", '\xe2\x86\x93 SAQUINAVIR', 'COADMINISTRATION MAY LEAD TO LOSS OF VIROLOGIC RESPONSE AND POSSIBLE RESISTANCE TO INVIRASE OR TO THE CLASS OF PROTEASE INHIBITORS (SEE WARNINGS ).', 'GARLIC CAPSULES', '\xe2\x86\x93 SAQUINAVIR', 'COADMINISTRATION OF GARLIC CAPSULES AND SAQUINAVIR IS NOT RECOMMENDED DUE TO THE POTENTIAL FOR GARLIC CAPSULES TO INDUCE THE METABOLISM OF SAQUINAVIR WHICH MAY RESULT IN SUB-THERAPEUTIC SAQUINAVIR CONCENTRATIONS.']